Barclays Rates Guardant Health (GH) buy, $150 Price Target

Barclays maintains a Buy rating on Guardant Health with a $150 price target, a 4.94% upside from the current price.

By EarningsIQ Research Desk · Published Jun 24, 2026, 11:01 AM EDT · Updated Jun 26, 2026, 3:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays rated Guardant Health, Inc. ($GH) "buy" with a $150 price target on June 24, 2026.

Since the rating, $GH is up 24.7% after 1 week, up 7.6% after 1 month and up 15.8% to date (from the $136.96 close on Jun 24, 2026).

GH Guardant Health, Inc.

$158.60 +55.89% year to date

Daily close · Oct 16, 2026

Key Points

Barclays reiterated its Buy rating on Guardant Health, Inc. (GH) on June 24, 2026, with a price target of $150.
Barclays's $150 price target implies 4.94% upside from Guardant Health, Inc.'s ($GH) current $142.94 share price.
Shares of NasdaqGS:GH traded near $130.83 on Wednesday, with a market cap of approximately $17.08 billion.
Guardant Health is a healthcare company specializing in precision oncology, headquartered in Palo Alto, California.

Get $GH trade alerts by text

We text you when insiders, Congress or big funds trade $GH. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Guardant Health, Inc. alert may contain errors. Disclosures

Barclays has reiterated its Buy rating on Guardant Health, Inc. (NasdaqGS:GH) as of June 24, 2026. Analyst Luke Sergott set a price target of $150 for the precision oncology company, maintaining confidence in its growth potential.

Analyst rating track record

Barclays vs. the S&P 500

YTD return +22.25% hypothetical

All-time return +39.40% S&P 500 +39.12%

vs. S&P 500 +0.28% ahead of the index

Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.

Guardant Health, Inc. Stock Down 13.8%

Shares of Guardant Health traded near $130.83 on Wednesday. The company, which specializes in diagnostics and research, has a market cap of about $17.08 billion. Its forward P/E ratio is not meaningful as it isn't profitable, with an EPS of -$3.40. Guardant Health's stock has ranged from $40.35 to $135.00 over the past 52 weeks. The stock's 50-day moving average is $105.79, and its 200-day moving average is $93.91. Guardant Health maintains a strong liquidity position with a current ratio of 4.68 and a quick ratio of 4.25.

12-month forecast

$GH price target

Guardant Health, Inc. daily closes and this analyst's $150 target. Not advice.

Recent Earnings

In its latest earnings report, Guardant Health posted a revenue of approximately $1.08 billion, reflecting a growth of 48.3%. Despite this growth, the company recorded a net margin of -40.1%. The next earnings announcement is expected on July 29, 2026.

Insider Buying and Selling at Guardant Health, Inc.

Recent insider activity at Guardant Health includes planned sales by Tariq Musa and Myrtle Potter, who sold 1,951 and 1,556 shares respectively at an average price of $131.16 on June 22, 2026. Additionally, Roberto Mignone made several transactions, including both buying and selling 264 shares on various dates without a specified price.

Analysts Set New Price Targets

On June 24, 2026, Barclays maintained its Buy rating on Guardant Health with a $150 price target. Earlier in June, RBC Capital initiated coverage with a Buy rating and a $185 target, while Mizuho maintained a Buy rating with a $175 target. Goldman Sachs also initiated coverage with a Buy rating and a $165 target.

About Guardant Health

Guardant Health, Inc. is a healthcare company focused on precision oncology. It provides blood and tissue tests, as well as data sets, to advance cancer research and therapy development. The company offers various tests, including the Guardant360 CDx test and the Guardant Reveal test, which are designed to detect cancer at the molecular level. Headquartered in Palo Alto, California, Guardant Health employs about 2,490 people and is led by CEO Dr. Helmy Eltoukhy.

Bottom Line

Barclays' reiterated Buy rating on Guardant Health highlights ongoing confidence in the company's potential. Investors often track such analyst ratings as part of their decision-making process. As a reminder, these ratings reflect opinions at the time of publication and may not indicate future performance.